Latest Patent Protection News

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

INOVIQ Limited clarifies recent share price movements, confirming no undisclosed material information while highlighting an imminent ASCO presentation and provisional patent application tied to its EXO-OC ovarian cancer test.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.

EcoGraf Limited has been granted a second Australian patent for its HFfree® purification technology, reinforcing its position in the sustainable battery materials market. This patent extends protection for its innovative graphite purification process critical to lithium-ion battery anode production and recycling.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

BluGlass Limited has achieved a world-record 1250mW single-mode GaN laser chip and strengthened its commercial pipeline with a $120,000 repeat order, positioning itself for rapid growth in photonics markets.

Sparc Technologies has progressed to Stage 2 of its Sparc Hydrogen joint venture with pilot plant commissioning slated for mid-2025, while also securing its first patent for photocatalytic water splitting technology in Morocco. Concurrently, its graphene-based additive ecosparc® demonstrates promising field trial results, underpinning commercial momentum.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.